Daniel Gruskin - 06 Aug 2021 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Role
Chief Medical Officer
Signature
/s/ Jonathan Quick, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
06 Aug 2021
Net transactions value
-$6,381
Form type
4
Filing time
10 Aug 2021, 18:31:22 UTC
Previous filing
20 May 2021
Next filing
03 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LOGC Common Stock Options Exercise +4,798 4,798 06 Aug 2021 Direct F1
transaction LOGC Common Stock Sale $6,381 -1,467 -31% $4.35 3,331 09 Aug 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Restricted Stock Units Options Exercise $0 -4,798 -100% $0.000000* 0 06 Aug 2021 Common Stock 4,798 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company").
F2 This sale was made automatically by the Company to cover tax withholding obligations in connection with the vesting and settlement of the RSUs reported in the row above.
F3 These RSUs vested on August 6, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan.